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Parasitic infections are a major global health burden. The
impact of debilitating diseases caused by parasites is greatest
among those who struggle to meet their daily basic needs
and access basic health care services in low-income countries.
However, persons who have or are at risk for parasitic infec-
tions are present in every income and social strata, and resi-
dents of the United States and other developed nations are
not unaffected. For some persons living in the United States,
these parasitic infections are acquired in their own immediate
environment; for example, exposure to feces from domestic
dogs or cats puts children at risk for toxocariasis and toxo-
plasmosis. For others, chronic parasitic infections acquired
years ago in other areas of the world can manifest with severe
illness later in life, such as neurocysticercosis leading to adult–
onset epilepsy or Chagas disease leading to severe cardio-
myopathy requiring heart transplant. We know much less
than we should about the health and economic burden and
impact of parasitic diseases in developed countries, including
the United States (Table 1).1
This issue of the American Journal of Tropical Medicine
and Hygiene features brief reviews of five parasitic infec-
tions that remain a significant health problem in the United
States: Chagas disease, cysticercosis, toxocariasis, toxoplas-
mosis, and trichomoniasis.2–6 These five diseases, which are
among those that Centers for Disease Control and Preven-
tion (CDC) refers to as neglected parasitic infections (NPIs)
in the United States, have different epidemiologic profiles
and modes of transmission and require tailored prevention
and control strategies. However, in the United States these
NPIs share key characteristics, including 1) the surprisingly
large number of persons infected or at risk, especially those
living in poverty; 2) the potential for underreporting and
missed diagnoses, largely because of lack of clinician aware-
ness and poor availability of optimal diagnostic tests; and
3) the dearth of interventions that can prevent or cure ill-
ness. As a result of these issues, these diseases have not
received needed attention or resources in the United States.
These reviews are part of an effort to raise awareness and
promote public health actions that can be taken now with
available knowledge and tools and highlight areas for fur-
ther clinical and epidemiologic research and action.
Assessments and reviews of these diseases often highlight
the remarkable lack of information about who is at highest
risk for infection, how many people in the United States are
infected, and how to best intervene to prevent infection from
progressing to disease. Estimates of disease burden are often
based on serologic markers from cross-sectional population
studies that indicate a person has been infected but not
whether that person has active disease (e.g., toxoplasmosis
and toxocariasis).7,8 In addition, the estimates may be pro-
jected from geographically focused studies that might not
be representative of the true population burden (e.g., tricho-
moniasis, Chagas disease, and neurocysticercosis).9 The public
health community also has few good estimates of the eco-
nomic burden imposed by these NPIs. Limited estimates,
such as one study that examined hospital discharge data on
neurocysticercosis for 2009 in California estimated state-
wide hospital charges and costs at $17 million and $5 mil-
lion, respectively, suggesting that the nationwide economic
burden is considerable.10 The morbidity caused by NPIs
extends across the lifespan, including blindness or severe
developmental deficits in children (toxocariasis, toxoplas-
mosis), infertility and poor birth outcomes (trichomoniasis)
or epilepsy (neurocysticercosis) in young adults, and cardio-
myopathy sometimes requiring transplant in middle age
adults (Chagas disease). Symptoms can develop in persons
with Chagas disease, toxoplasmosis, and cysticercosis years
after an initial mildly symptomatic or subclinical infection.
Furthermore, a few intriguing studies have shown associations
between some NPIs and complex chronic diseases with enor-
mous health impact, such as studies linking antibody evidence
of Toxoplasma infection and mental illness or Toxocara infec-
tion and asthma.11–13
Appropriate and timely medical management of a person
with an NPI is critical, but the public health actions needed
to identify and prevent infection and disease fall to the
under-resourced and overburdened public health sector. For
example, a person with neurocysticercosis needs careful
medical management to control neurologic symptoms but
can also benefit from public health follow up because test-
ing of household members for taeniasis (intestinal Taenia
solium infection) might identify and treat the typically asymp-
tomatic human source of the person’s infection. Women bear
most of the burden of symptomatic trichomoniasis, and they
can be successfully treated with a short course of metronida-
zole in clinics for women’s health or sexually transmitted infec-
tions. However, without finding and treating their male
partners, reinfection is likely. Among U.S. residents, Chagas
disease risk is much higher among persons who previously
lived in rural and impoverished areas in Mexico, Central
America, or South America, where the vector of Chagas
disease, the triatomine or kissing bug, is commonly found
near or in dwellings. Chagas disease patients are increas-
ingly being identified during routine blood donor screen-
ing; their health care providers often turn to the public
health sector for assistance with diagnosis and treatment
decisions. Furthermore, identification of a person with Chagas
disease can trigger additional recommendations such as test-
ing others in the family (for example, children of an infected
mother). Targeted screening programs in some immigrant
communities might identify other infected persons and
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thereby reduce their risk of later stage severe complications or
perinatal transmission.
Clearly, additional work is needed in three major areas to
advance prevention and control of these diseases: 1) better
estimates of disease burden and a better understanding of
how to reduce the risk of acquiring NPIs; 2) improved diag-
nostic and treatment methods; and 3) programmatic expan-
sion of currently available, proven interventions (Table 2).
Estimating disease burden and identifying practical and effec-
tive risk reduction programs is challenging for diseases that
frequently go unnoticed, especially because most NPIs in
the United States disproportionately affect persons with
reduced access to adequate health care, such as those living
in poverty or in immigrant communities. Targeted surveil-
lance or screening programs in populations most likely to be
at risk could be a first step in improving burden estimates, at
relatively low cost. For example, community-based screening
surveys in areas with high concentrations of Latino immigrants
might efficiently identify the proportion of area residents who
have asymptomatic Chagas disease or taeniasis and should be
evaluated for treatment.
We must develop more accurate diagnostic testing methods
that can be made widely available, especially tests able to dis-
tinguish past exposure from current infection. For example,
persons who test positive for Chagas disease as part of rou-
tine blood donor screening typically require additional antibody
tests that are performed at CDC before diagnosis is confirmed
and treatment is provided. Sometimes these test results are not
able to definitively confirm or exclude the diagnosis, leaving
the clinician uncertain about the merits of advising treatment.
We remain uncertain about whether an antibody test that is
positive for toxocariasis might indicate continued infection. A
positive IgM test result for acute Toxoplasma infection in a
pregnant woman leaves the patient and healthcare provider
in the agonizing position of being uncertain whether the test
result is a false positive or an indicator that the fetus is
at high risk for congenital toxoplasmosis. Additional testing
is not always able to provide definitive answers.
For some persons, NPIs treatment options are limited or
suboptimal. Drug therapies recommended for treatment
of Chagas disease are not approved by the U.S. Food and
Drug Administration and are available only from CDC. It
is not clear how to best treat women in early pregnancy with
evidence of acute toxoplasmosis. There is evidence that some
Trichomonas strains are developing resistance to metroni-
dazole, and new drugs are unlikely to be available in the near
future. Therefore, in the coming years we will need a robust
program of research and development to design, develop, and
implement new interventions.
However, there are some interventions we can and should
make right now to attack these diseases, including deworming
dogs and cats, rapid and safe pickup of pet feces, covering sand-
boxes to reduce animal fecal contamination, and appropriate
cooking of meat to help prevent toxoplasmosis, to name but a
few. Increasing knowledge of NPIs among health care providers
and the at-risk population can lead to more of those affected
being diagnosed and receiving appropriate treatment.
The articles in this issue highlight the urgent need to char-
acterize and reduce the impact of NPIs in the United States.
The perception that parasitic diseases are no longer relevant or
important is a major impediment to implementing currently
available control and prevention strategies. To support efforts
Table 1
Estimates of burden and impact of neglected parasitic infections
More than 300,000 persons living in the United States are infected
with Trypanosoma cruzi, the cause of Chagas disease, and more
than 300 infected babies are born every year in the United States
At least 1,000 incident hospitalizations for symptomatic
neurocysticercosis per year in the United States
At least 14% of the U.S. population has been exposed to Toxocara,
and each year at least 70 people, most of them children, are blinded
by ocular toxocariasis
More than 60 million persons in the United States are chronically
infected with Toxoplasma gondii; new infections in pregnant
women can lead to birth defects and infections in
immunocompromised persons can be fatal
Trichomoniasis is a major cause of infertility and preterm labor and
low birthweight, and each year 1.1 million people are newly
infected with Trichomonas in the United States
Table 2
Key knowledge and intervention gaps for neglected parasitic infections*
Assess disease burden and risk factors
Burden of congenital Chagas disease; role of autochthonous transmission
Burden of cardiac disease caused by Trypanosoma cruzi and risk factors for severe sequelae among persons infected
Burden of visceral toxocariasis and natural history of disease
Burden of neurocysticercosis
Trichomoniasis and increased risk of HIV and adverse outcomes of pregnancy
Role of Toxoplasma gondii infection in psychiatric diseases
Role of toxocariasis in allergic diseases
Improved diagnostic tests and treatments
Chagas disease tests and drugs
Drug-resistant trichomoniasis: alternative drugs, better test to determine resistance
Antibody tests using recombinant antigens to better identify active neurocysticercosis and monitor response to treatment
Evaluation of drug regimens for treatment of pregnant women with acute toxoplasmosis
Appropriate treatment of various manifestations of neurocysticercosis
Optimal treatment for visceral and ocular toxocariasis
Programmatic expansion of proven interventions
Screening and treating contacts of neurocysticercosis cases for taeniasis
Deworming of dogs and cats
Covering sand boxes to reduce exposure to animal feces
Health education to prevent toxoplasmosis: cooking meat adequately, pregnant women avoiding contact with cat litter
Appropriate clinical management to prevent Chagas disease progression
Treatment of male partners of women who have trichomoniasis
*HIV = human immunodeficiency virus.
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to reduce NPIs, CDC serves as a national and global resource
for diagnosis through DPDx (the CDC web-based diagnostic
resource for parasitic diseases); provides investigational drugs
available through its drug service to treat parasitic infections
when U.S. Food and Drug Administration–approved drugs
are not available; supplies comprehensive information about
NPIs to public health departments, healthcare providers
and the public; and continues to work on developing better
diagnostic tools. The NPIs in the United States are part of
the global burden of parasitic diseases, and strategies that
reduce or eliminate them in the United States can someday be
applied globally.
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